The Top Challenge Of Telemedicine (Video Content)

The U.S. Food and Drug Administration has released a discussion paper outlining its initial framework for regulating generative AI-enabled medical devices, proposing a two-axis risk assessment approach and a novel competency-based premarket evaluation system. With public comments due by October 19, 2026, this represents a critical opportunity for device manufacturers and stakeholders to shape the regulatory landscape for this transformative technology.

On Friday, California Office of Health Care Affordability (“OHCA”) published proposed final regulations that implement a 2026 law that significantly expanded OHCA’s review authority over health care transactions involving private equity (“PE”) groups, hedge funds, and management services organizations (“MSOs”). Stakeholders involved in California health care transactions should re-assess whether their ongoing or contemplated transactions are implicated by these regulations, because newly covered transactions will need to comply with the 90-day advance notice requirement established in the original OHCA regulations.

The FDA, in collaboration with federal partners, held a landmark public hearing on September 14, 2026, to gather input on the future therapeutic use of psychedelic drugs, drawing over 18,000 registered attendees. This hearing represents one of the earliest implementations of Executive Order 14401, which directs federal agencies to expedite research, review, and approval of psychedelic drugs for serious mental health conditions.

Over the past year, industry has had a front row seat as the Food and Drug Administration (“FDA” or the “Agency”) decides just how much leeway it wants to afford the manufacture, marketing, and sale of peptide products, and just where it wants to draw the line. Despite the recent decision of FDA’s Pharmacy Compounding Advisory Committee (“PCAC”) to recommend a number of peptides for inclusion on the 503A bulks list process — a move that represents a potentially more permissive stance toward peptide regulation, at least in terms of what can and cannot be compounded under 503A...

On November 17, 2022, FDA posted warning letters to 7 companies for selling different dietary supplements with claims that caused the products to be "drugs" in violation..

The healthcare mergers and acquisitions (M&A) market began 2025 with a slower start than expected given the easing headwinds and building momentum at the end of last year...

ONn February 3, 2026, Congress enacted the Consolidated Appropriations Act, 2026, marking a watershed moment in the regulation of pharmacy benefit managers (PBMs).

For those that have been awaiting the federal government’s issuance of the final rules modifying the Health Insurance Portability and Accountability Act (HIPAA) Privacy and Security regulations...

On September 15, 2026, a dozen independent pharmacies in Arkansas filed a lawsuit against Express Scripts Inc. (ESI), a pharmacy benefit manager (PBM), alleging that it reimbursed the pharmacies...

The Centers for Medicare & Medicaid Services has launched a groundbreaking 10-year Accountable Care Organization program that promises unprecedented benchmark stability and financial flexibility for healthcare providers. With applications due by May 17, 2026, the Long-term Enhanced ACO Design (LEAD) Model introduces innovative payment mechanisms, specialist integration pathways, and enhanced support for high-needs populations that could fundamentally reshape value-based care delivery through 2036.

The United Auto Workers Union strike against the Detroit Three automakers that began on September 15th continues with no immediate resolution in sight.

Louis Lehot is a legal professional at Foley & Lardner LLP, specializing in corporate and transactional matters. His practice focuses on advising clients across various business and legal challenges. Contact information and professional details are provided for those seeking his expertise.

"Greenwashing" is the term for a company's exaggerated, misleading, or unsupported claims about its environmental practices.

Rosekind has served for the past four years as a member of the National Transportation Safety Board. Rosekind focused on accident investigations and human fatigue in his role at the NTSB.

The Department of Health and Human Services has issued a final rule that eliminates the Medicare Part D creditable coverage notice requirement for account-based group health plans, including ICHRAs, HRAs, FSAs, and HSAs. This regulatory change addresses longstanding administrative burdens and confusion caused by dual messaging requirements, marking a significant shift in how these benefit arrangements interact with Medicare Part D disclosure obligations.

On February 19, 2026, the U.S. Department of the Treasury’s Office of Foreign Assets Control (OFAC) sanctioned a luxury timeshare resort near Puerto Vallarta connected to Cartel de Jalisco Nueva Generacion’s (CJNG).

Studies show that 70-90% of corporate mergers and acquisitions fail to achieve their stated goals, making governance discipline critical as deal activity accelerates. This framework guides directors through the fiduciary duties, key questions, documentation requirements, and common pitfalls they must navigate when overseeing a significant acquisition. From evaluating strategic rationale and synergies to managing conflicts of interest and ensuring adequate due diligence, directors who approach acquisitions w

Connect with Foley & Lardner LLP's intellectual property and litigation professionals, including Vanessa Miller, Ann-Marie Uetz, and Nicholas Ellis, who provide expert legal counsel across various practice areas.

As U.S. utilities commit record capital to grid expansion, equipment procurement has emerged as a critical constraint. Lead times for transformers now stretch beyond two years, while material scarcity, inflation, and labor shortages compound delays across conductor, switchgear, and substation components.

The United Arab Emirates' departure from OPEC in April 2026 represents the most significant defection in the oil cartel's 66-year history. What drove this founding-era member to abandon nearly six decades of coordinated production policy, and how will this decision reshape global energy markets as the UAE pursues an independent production strategy unconstrained by quota limitations?